Pulmonx Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]
Pulmonx Corporation (LUNG)
US:NASDAQ Investor Relations:
investor.prolunginc.com/investor-relations
Company Research
Source: Yahoo! Finance
global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Delivered $90.5 million in worldwide revenue for the full year of 2025, an 8% increase over the prior year and an increase of 7% on a constant currency basis Achieved worldwide revenue of $22.6 million for the fourth quarter of 2025, a 5% decrease over the same period last year and a decrease of 7% on a constant currency basis Realized gross margin of 78% in the fourth quarter of 2025 and 74% for the full year of 2025 Refinanced existing debt, securing up to $60 million in committed capital under a new 5-year interest-only credit facility that extends the debt maturity out to 2031 Executed cost restructuring initiative to reduce operating expenses while maintaining key commercial and clinical investments in growth "While our recent performance reflects a period of transition, we see a substantial
Show less
Read more
Impact Snapshot
Event Time:
LUNG
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LUNG alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LUNG alerts
High impacting Pulmonx Corporation news events
Weekly update
A roundup of the hottest topics
LUNG
News
- Pulmonx (LUNG) had its price target lowered by Canaccord Genuity Group Inc. from $6.00 to $5.00. They now have a "buy" rating on the stock.MarketBeat
- Pulmonx (LUNG) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $14.00 price target on the stock.MarketBeat
- Pulmonx Corp (LUNG) Q4 2025 Earnings Call Highlights: Strategic Restructuring and Sales Force ... [Yahoo! Finance]Yahoo! Finance
- Pulmonx Q4 Earnings Call Highlights [Yahoo! Finance]Yahoo! Finance
- Pulmonx (LUNG) Q4 2025 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
LUNG
Earnings
- 3/4/26 - Beat
LUNG
Analyst Actions
- 3/5/26 - Canaccord Genuity
LUNG
Sec Filings
- 3/10/26 - Form S-8
- 3/10/26 - Form 10-K
- 3/9/26 - Form SCHEDULE
- LUNG's page on the SEC website